Publications

Publications by Åslaug Helland

179 publications found

Publications 2025

1. Brant SB, Børø S, Jonasson C, Helland Å, Thoresen S (2025)
   Comparative Effectiveness of First-Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population-Based Cohort Study
   Clin Pharmacol Ther, 117 (4), 1123-1130
   DOI 10.1002/cpt.3591, PubMed 39916352
2. Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
   Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
   Front Oncol, 15, 1506041
   DOI 10.3389/fonc.2025.1506041, PubMed 40052133
3. Rakaee M, Tafavvoghi M, Ricciuti B, Alessi JV, Cortellini A, Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Hidalgo Filho CM, Di Federico A, Jabar F, Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland Å, Sholl LM, Awad MM, Kwiatkowski DJ (2025)
   Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
   JAMA Oncol, 11 (2), 109-118
   DOI 10.1001/jamaoncol.2024.5356, PubMed 39724105

Publications 2024

1. Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
   Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
   Acta Oncol, 63, 487-490
   DOI 10.2340/1651-226X.2024.24954, PubMed 38910311
2. Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
   Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
   Int J Cancer, 155 (2), 282-297
   DOI 10.1002/ijc.34915, PubMed 38489486
3. Chen L, Wang X, Xie N, Zhang Z, Xu X, Xue M, Yang Y, Liu L, Su L, Bjaanæs M, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Christiani DC, Chen F, Zhang R (2024)
   A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
   Mol Oncol, 19 (1), 173-187
   DOI 10.1002/1878-0261.13766, PubMed 39630602
4. Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
   Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
   Front Immunol, 15, 1480183
   DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
5. Helland Å (2024)
   [Not Available]
   Tidsskr Nor Laegeforen, 144 (15)
   DOI 10.4045/tidsskr.24.0603, PubMed 39692664
6. Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
   [Raising the quality of cancer treatment]
   Tidsskr Nor Laegeforen, 144 (1)
   DOI 10.4045/tidsskr.23.0740, PubMed 38258713
7. Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
   UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
   Eur J Cancer, 202, 113973
   DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
8. Mahon P, Chatzitheofilou I, Dekker A, Fernández X, Hall G, Helland A, Traverso A, Van Marcke C, Vehreschild J, Ciliberto G, Tonon G (2024)
   A federated learning system for precision oncology in Europe: DigiONE
   Nat Med, 30 (2), 334-337
   DOI 10.1038/s41591-023-02715-8, PubMed 38195748
9. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A (2024)
   Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
   Acta Oncol, 63, 213-219
   DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
10. Nilssen Y, Brustugun OT, Fjellbirkeland L, Grønberg BH, Haram PM, Helbekkmo N, Helland Å, Wahl SGF, Aanerud M, Solberg S (2024)
    Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends
    Clin Lung Cancer, 25 (5), e221-e228.e3
    DOI 10.1016/j.cllc.2024.04.002, PubMed 38692990
11. Nilssen Y, Brustugun OT, Fjellbirkeland L, Helland Å, Møller B, Wahl SGF, Solberg S (2024)
    Distribution and characteristics of malignant tumours by lung lobe
    BMC Pulm Med, 24 (1), 106
    DOI 10.1186/s12890-024-02918-w, PubMed 38439038
12. Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
    Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
    Front Oncol, 14, 1412716
    DOI 10.3389/fonc.2024.1412716, PubMed 39148905
13. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
    IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
    Acta Oncol, 63, 379-384
    DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
14. Ringborg U, von Braun J, Celis J, Baumann M, Berns A, Eggermont A, Heard E, Heitor M, Chandy M, Chen CJ, Costa A, De Lorenzo F, De Robertis EM, Dubee FC, Ernberg I, Gabriel M, Helland Å, Henrique R, Jönsson B, Kallioniemi O, Korbel J, Krause M, Lowy DR, Michielin O, Nagy P et al. (2024)
    Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023
    Mol Oncol, 18 (2), 245-279
    DOI 10.1002/1878-0261.13575, PubMed 38135904
15. Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
    PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
    Acta Oncol, 63, 385-391
    DOI 10.2340/1651-226X.2024.34791, PubMed 38779910
16. Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
    Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
    Eur J Nucl Med Mol Imaging, 52 (2), 693-707
    DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Publications 2023

1. Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
   Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
   Acta Oncol, 62 (12), 1642-1648
   DOI 10.1080/0284186X.2023.2264484, PubMed 37801361
2. Helland Å, Myklebust TÅ, Conte S, Frederiksen LE, Aarøe J, Enerly E (2023)
   EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study
   Cancer Treat Res Commun, 38, 100785
   DOI 10.1016/j.ctarc.2023.100785, PubMed 38190787
3. Huynh TM, Dale E, Falk RS, Hellebust TP, Astrup GL, Malinen E, Edin NFJ, Bjordal K, Herlofson BB, Kiserud CE, Helland Å, Amdal CD (2023)
   Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters
   Radiother Oncol, 190, 110044
   DOI 10.1016/j.radonc.2023.110044, PubMed 38061420
4. Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
   Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
   Front Oncol, 13, 1217424
   DOI 10.3389/fonc.2023.1217424, PubMed 37476372
5. Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
   Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
   Eur J Cancer, 194, 113278
   DOI 10.1016/j.ejca.2023.113278, PubMed 37820553
6. Nilssen Y, Solberg S, Brustugun OT, Møller B, Sundset A, Wahl SGF, Helland Å (2023)
   Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
   Eur J Cardiothorac Surg, 64 (1)
   DOI 10.1093/ejcts/ezad244, PubMed 37348858
7. Ottesen JA, Yi D, Tong E, Iv M, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Bjørnerud A, Zaharchuk G, Grøvik E (2023)
   2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data
   Front Neuroinform, 16, 1056068
   DOI 10.3389/fninf.2022.1056068, PubMed 36743439
8. Skoie IM, Skogås JG, Langø T, Myhr KM, Myhre PL, Goll R, Fretland SØ, Helland Å (2023)
   New centres to carry out more clinical trials in Norway
   Tidsskr Nor Laegeforen, 143 (2)
   DOI 10.4045/tidsskr.22.0722, PubMed 36718905
9. Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2023)
   Erratum: "MRI pulse sequence integration for deep-learning-based brain metastases segmentation"
   Med Phys, 50 (8), 5294
   DOI 10.1002/mp.16594, PubMed 37573581

Publications 2022

1. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
   Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
   Front Immunol, 13, 875152
   DOI 10.3389/fimmu.2022.875152, PubMed 35911763
2. Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
   Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer
   Front Immunol, 13, 1051156
   DOI 10.3389/fimmu.2022.1051156, PubMed 36263024
3. Børø S, Thoresen S, Helland Å (2022)
   Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway
   Front Oncol, 12, 1017902
   DOI 10.3389/fonc.2022.1017902, PubMed 36523970
4. Chen J, Song Y, Li Y, Wei Y, Shen S, Zhao Y, You D, Su L, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Shen H, Christiani DC, Zhang R, Chen F (2022)
   A trans-omics assessment of gene-gene interaction in early-stage NSCLC
   Mol Oncol, 17 (1), 173-187
   DOI 10.1002/1878-0261.13345, PubMed 36408734
5. Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT (2022)
   Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
   Transl Lung Cancer Res, 11 (6), 953-963
   DOI 10.21037/tlcr-21-995, PubMed 35832438
6. Helland Å, Andersen KK, Myklebust TÅ, Johannesen TB, Aarøe J, Enerly E (2022)
   EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study
   Cancer Treat Res Commun, 33, 100636
   DOI 10.1016/j.ctarc.2022.100636, PubMed 36155129
7. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
8. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
9. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
   Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
   Mol Oncol, 17 (3), 487-498
   DOI 10.1002/1878-0261.13330, PubMed 36330681
10. Ji X, Lin L, Fan J, Li Y, Wei Y, Shen S, Su L, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Zhang R, Chen F, Christiani DC (2022)
    Epigenome-wide three-way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of early-stage NSCLC
    Mol Oncol, 16 (3), 717-731
    DOI 10.1002/1878-0261.13167, PubMed 34932879
11. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
    Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    Front Oncol, 12, 873532
    DOI 10.3389/fonc.2022.873532, PubMed 35574381
12. Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
    A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
    Front Oncol, 12, 1031232
    DOI 10.3389/fonc.2022.1031232, PubMed 36439452
13. Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    Cancer Res Commun, 2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555
14. Solberg S, Nilssen Y, Terje Brustugun O, Magnus Haram P, Helland Å, Møller B, Strand TE, Gyrid Freim Wahl S, Fjellbirkeland L (2022)
    Concordance between clinical and pathology TNM-staging in lung cancer
    Lung Cancer, 171, 65-69
    DOI 10.1016/j.lungcan.2022.07.014, PubMed 35926242
15. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
16. Umu SU, Langseth H, Zuber V, Helland Å, Lyle R, Rounge TB (2022)
    Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
    Elife, 11
    DOI 10.7554/eLife.71035, PubMed 35147498

Publications 2021

1. Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
   Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
   Front Oncol, 11, 674731
   DOI 10.3389/fonc.2021.674731, PubMed 34109123
2. Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
   Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
   BMC Cancer, 21 (1), 1089
   DOI 10.1186/s12885-021-08811-7, PubMed 34625038
3. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT (2021)
   Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
   Acta Oncol, 60 (12), 1565-1571
   DOI 10.1080/0284186X.2021.1973092, PubMed 34486915
4. Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
   [Immunotherapy for malignant pleural mesothelioma]
   Tidsskr Nor Laegeforen, 141
   DOI 10.4045/tidsskr.21.0503, PubMed 34505475
5. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
   Immunotherapy in malignant pleural mesothelioma
   Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
6. Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
   The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
   Front Immunol, 12, 764596
   DOI 10.3389/fimmu.2021.764596, PubMed 34868011
7. Grøvik E, Yi D, Iv M, Tong E, Nilsen LB, Latysheva A, Saxhaug C, Jacobsen KD, Helland Å, Emblem KE, Rubin DL, Zaharchuk G (2021)
   Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study
   NPJ Digit Med, 4 (1), 33
   DOI 10.1038/s41746-021-00398-4, PubMed 33619361
8. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
   NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
   J Transl Med, 19 (1), 232
   DOI 10.1186/s12967-021-02905-3, PubMed 34059094
9. Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
   COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
   Front Oncol, 11, 652535
   DOI 10.3389/fonc.2021.652535, PubMed 33842366
10. Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Okamoto I, van der Leest C, Rich P, Hung JY, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, Bar J (2021)
    Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
    J Thorac Oncol, 16 (9), 1570-1581
    DOI 10.1016/j.jtho.2021.03.012, PubMed 33823285
11. Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ et al. (2021)
    Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms
    Nat Cancer, 2 (11), 1224-1242
    DOI 10.1038/s43018-021-00259-9, PubMed 34870237
12. Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S (2021)
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
    Lung Cancer, 157, 9-16
    DOI 10.1016/j.lungcan.2021.05.017, PubMed 34051652
13. Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2021)
    MRI pulse sequence integration for deep-learning-based brain metastases segmentation
    Med Phys, 48 (10), 6020-6035
    DOI 10.1002/mp.15136, PubMed 34405896
14. Öjlert ÅK, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, Chee J, Helland Å (2021)
    Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor
    Mol Oncol, 15 (11), 2958-2968
    DOI 10.1002/1878-0261.13082, PubMed 34402187

Publications 2020

1. Abravan A, Eide HA, Helland Å, Malinen E (2020)
   Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
   Clin Transl Radiat Oncol, 22, 15-21
   DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373
2. Brustugun OT, Sorhaug S, Gronberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland A, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
   Lung cancer: Improved prognosis presents capacity challenges
   Tidsskr. Nor. Laegeforen., 140 (5), 432-434
3. Brustugun OT, Sørhaug S, Grønberg BH, Aanerud M, Al-Zubayidy MMZ, Fjellbirkeland L, Helland Å, Berg J, Andreassen B, Paulsen EE, Haram PM, Ashraf H, Wahl SGF (2020)
   [Lung cancer: Improved prognosis results in capacity challenges]
   Tidsskr Nor Laegeforen, 140 (5)
   DOI 10.4045/tidsskr.20.0014, PubMed 32238965
4. Chen C, Wei Y, Wei L, Chen J, Chen X, Dong X, He J, Lin L, Zhu Y, Huang H, You D, Lai L, Shen S, Duan W, Su L, Shafer A, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Zhang R et al. (2020)
   Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
   Aging (Albany NY), 12 (11), 10642-10662
   DOI 10.18632/aging.103284, PubMed 32511103
5. Digernes I, Nilsen LB, Grøvik E, Bjørnerud A, Løvland G, Vik-Mo E, Meling TR, Saxhaug C, Helland Å, Jacobsen KD, Geier O, Emblem KE (2020)
   Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
   Phys Med Biol, 65 (22), 225020
   DOI 10.1088/1361-6560/abb71a, PubMed 33200748
6. Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
   Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
   Lung Cancer, 143, 27-35
   DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138
7. Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
   Antibody combinations for optimized staining of macrophages in human lung tumours
   Scand J Immunol, 92 (1), e12889
   DOI 10.1111/sji.12889, PubMed 32299134
8. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
   Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
   Front Oncol, 10, 590755
   DOI 10.3389/fonc.2020.590755, PubMed 33324562
9. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
   Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
   Int J Cancer, 147 (10), 2957-2966
   DOI 10.1002/ijc.33121, PubMed 32468587
10. Ji X, Lin L, Shen S, Dong X, Chen C, Li Y, Zhu Y, Huang H, Chen J, Chen X, Wei L, He J, Duan W, Su L, Jiang Y, Fan J, Guan J, You D, Shafer A, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M et al. (2020)
    Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
    Mol Oncol, 14 (11), 2759-2774
    DOI 10.1002/1878-0261.12785, PubMed 33448640
11. Nilsen LB, Digernes I, Grøvik E, Saxhaug C, Latysheva A, Geier O, Breivik B, Sætre DO, Jacobsen KD, Helland Å, Emblem KE (2020)
    Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
    Neurooncol Adv, 2 (1), vdaa028
    DOI 10.1093/noajnl/vdaa028, PubMed 32642687
12. Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
    The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
    Scand J Immunol, 92 (2), e12893
    DOI 10.1111/sji.12893, PubMed 32433774
13. Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
    A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
    Mol Oncol, 14 (2), 235-247
    DOI 10.1002/1878-0261.12620, PubMed 31851411
14. Zhang R, Chen C, Dong X, Shen S, Lai L, He J, You D, Lin L, Zhu Y, Huang H, Chen J, Wei L, Chen X, Li Y, Guo Y, Duan W, Liu L, Su L, Shafer A, Fleischer T, Moksnes Bjaanæs M, Karlsson A, Planck M, Wang R, Staaf J et al. (2020)
    Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
    Chest, 158 (2), 808-819
    DOI 10.1016/j.chest.2020.01.048, PubMed 32113923
15. Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
    Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
    Acta Oncol, 60 (2), 149-156
    DOI 10.1080/0284186X.2020.1854851, PubMed 33356733

Publications 2019

1. Abravan A, Eide HA, Løndalen AM, Helland Å, Malinen E (2019)
   Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer
   Mol Imaging Biol, 21 (2), 391-398
   DOI 10.1007/s11307-018-1226-7, PubMed 29916117
2. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
   A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
   J Mammary Gland Biol Neoplasia, 24 (2), 163-175
   DOI 10.1007/s10911-018-09423-x, PubMed 30613869
3. Dong X, Zhang R, He J, Lai L, Alolga RN, Shen S, Zhu Y, You D, Lin L, Chen C, Zhao Y, Duan W, Su L, Shafer A, Salama M, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Wei Y, Chen F et al. (2019)
   Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma
   Aging (Albany NY), 11 (16), 6312-6335
   DOI 10.18632/aging.102189, PubMed 31434796
4. Halvorsen AR, Ragle Aure M, Õjlert ÅK, Brustugun OT, Solberg S, Nebdal D, Helland Å (2019)
   Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
   Mol Oncol, 13 (12), 2604-2615
   DOI 10.1002/1878-0261.12571, PubMed 31505091
5. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
   PathTracer: High-sensitivity detection of differential pathway activity in tumours
   Sci Rep, 9 (1), 16332
   DOI 10.1038/s41598-019-52529-3, PubMed 31704995
6. Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T (2019)
   EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
   PLoS One, 14 (1), e0204186
   DOI 10.1371/journal.pone.0204186, PubMed 30703089
7. Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L (2019)
   Increase in curative treatment and survival of lung cancer in Norway 2001-2016
   Eur J Epidemiol, 34 (10), 951-955
   DOI 10.1007/s10654-019-00536-z, PubMed 31313073
8. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
   Immune Cell Composition in Human Non-small Cell Lung Cancer
   Front Immunol, 9, 3101
   DOI 10.3389/fimmu.2018.03101, PubMed 30774636
9. Zhang R, Lai L, Dong X, He J, You D, Chen C, Lin L, Zhu Y, Huang H, Shen S, Wei L, Chen X, Guo Y, Liu L, Su L, Shafer A, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y et al. (2019)
   SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomic-smoking interaction analysis
   Mol Oncol, 13 (5), 1235-1248
   DOI 10.1002/1878-0261.12482, PubMed 30924596
10. Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC (2019)
    EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC
    Epigenetics, 14 (2), 118-129
    DOI 10.1080/15592294.2019.1573066, PubMed 30665327
11. Öjlert ÅK, Halvorsen AR, Nebdal D, Lund-Iversen M, Solberg S, Brustugun OT, Lingjaerde OC, Helland Å (2019)
    The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery
    Mol Oncol, 13 (5), 1166-1179
    DOI 10.1002/1878-0261.12475, PubMed 30854794

Publications 2018

1. Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å (2018)
   Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
   BMC Cancer, 18 (1), 739
   DOI 10.1186/s12885-018-4659-0, PubMed 30005623
2. Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK (2018)
   Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
   Lung Cancer, 122, 138-145
   DOI 10.1016/j.lungcan.2018.06.003, PubMed 30032822
3. Digernes I, Grøvik E, Nilsen LB, Saxhaug C, Geier O, Reitan E, Sætre DO, Breivik B, Reese T, Jacobsen KD, Helland Å, Emblem KE (2018)
   Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery
   Adv Radiat Oncol, 3 (4), 559-567
   DOI 10.1016/j.adro.2018.05.005, PubMed 30370356
4. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
   Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
   Adv Radiat Oncol, 3 (2), 130-138
   DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
5. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L (2018)
   Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
   J Thorac Oncol, 13 (12), 1906-1918
   DOI 10.1016/j.jtho.2018.08.2027, PubMed 30217492
6. George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM et al. (2018)
   Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
   Nat Commun, 9 (1), 1048
   DOI 10.1038/s41467-018-03099-x, PubMed 29535388
7. Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC (2018)
   DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients
   Cancer Epidemiol Biomarkers Prev, 27 (12), 1527-1535
   DOI 10.1158/1055-9965.EPI-18-0454, PubMed 30185536
8. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
   Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
   Acta Oncol, 57 (9), 1225-1231
   DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
9. Helland A (2018)
   Groundbreaking basic research
   Tidsskr. Nor. Laegeforen., 138 (20), 1905
10. Helland Å (2018)
    [Groundbreaking basic research]
    Tidsskr Nor Laegeforen, 138 (20)
    DOI 10.4045/tidsskr.18.0802, PubMed 30539600
11. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
    Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
    Mol Oncol, 12 (11), 1838-1855
    DOI 10.1002/1878-0261.12375, PubMed 30133130
12. Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC (2018)
    A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
    Mol Oncol, 12 (6), 913-924
    DOI 10.1002/1878-0261.12204, PubMed 29656435
13. Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
    N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
    Mol Oncol, 12 (6), 972-990
    DOI 10.1002/1878-0261.12312, PubMed 29698574
14. Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC (2018)
    Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
    Clin Epigenetics, 10, 41
    DOI 10.1186/s13148-018-0474-3, PubMed 29619118

Publications 2017

1. Abravan A, Eide HA, Knudtsen IS, Løndalen AM, Helland Å, Malinen E (2017)
   Assessment of pulmonary ¹⁸F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
   Clin Transl Radiat Oncol, 4, 57-63
   DOI 10.1016/j.ctro.2017.04.002, PubMed 29594209
2. Abravan A, Knudtsen IS, Eide HA, Løndalen AM, Helland Å, van Luijk P, Malinen E (2017)
   A new method to assess pulmonary changes using ¹⁸F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy
   Acta Oncol, 56 (11), 1597-1603
   DOI 10.1080/0284186X.2017.1349336, PubMed 28849707
3. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
   Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
   Oncotarget, 8 (34), 57121-57133
   DOI 10.18632/oncotarget.19078, PubMed 28915659
4. Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
   DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
   Oncotarget, 8 (1), 1074-1082
   DOI 10.18632/oncotarget.13718, PubMed 27911866
5. Halvorsen AR, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta MP, Beale P, Helland Å (2017)
   Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
   Dis Markers, 2017, 3098542
   DOI 10.1155/2017/3098542, PubMed 28293063
6. McGowan M, Kleinberg L, Halvorsen AR, Helland Å, Brustugun OT (2017)
   NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
   Genes Cancer, 8 (3-4), 497-504
   DOI 10.18632/genesandcancer.136, PubMed 28680534
7. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM, Zhang P, Mookerjee B, Johnson BE (2017)
   Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
   Lancet Oncol, 18 (10), 1307-1316
   DOI 10.1016/S1470-2045(17)30679-4, PubMed 28919011

Publications 2016

1. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
   Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
   Nat Genet, 48 (4), 374-86
   DOI 10.1038/ng.3521, PubMed 26928228
2. Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
   The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
   BMC Cancer, 16, 71
   DOI 10.1186/s12885-016-2104-9, PubMed 26858029
3. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin Transl Immunology, 5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
4. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
   Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
   Oncoimmunology, 5 (12), e1248015
   DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
5. Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å (2016)
   A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
   Oncotarget, 7 (24), 37250-37259
   DOI 10.18632/oncotarget.9363, PubMed 27191990
6. Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
   Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
   Mol Oncol, 11 (2), 220-234
   DOI 10.1002/1878-0261.12025, PubMed 28145100
7. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
   TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
   Front Genet, 7, 85
   DOI 10.3389/fgene.2016.00085, PubMed 27242894
8. Helland A (2016)
   MicroRNA-profiles in lung adenocarcinomas
   Expert Rev. Precis. Med. Drug Dev., 1 (5), 469-474
   DOI 10.1080/23808993.2016.1240011
9. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
   Subtype-specific micro-RNA expression signatures in breast cancer progression
   Int J Cancer, 139 (5), 1117-28
   DOI 10.1002/ijc.30142, PubMed 27082076
10. Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
    Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
    F1000Res, 5, 38
    DOI 10.12688/f1000research.7599.1, PubMed 27081474
11. Kongsgaard A, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    Diagn Pathol, 11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
12. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT (2016)
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
    Lung Cancer, 103, 52-57
    DOI 10.1016/j.lungcan.2016.11.018, PubMed 28024696
13. Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R et al. (2016)
    Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking
    Nat Genet, 49 (1), 65-74
    DOI 10.1038/ng.3722, PubMed 27869826

Publications 2015

1. Arnesen MR, Knudtsen IS, Rekstad BL, Eilertsen K, Dale E, Bruheim K, Helland Å, Løndalen AM, Hellebust TP, Malinen E (2015)
   Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps
   Acta Oncol, 54 (9), 1607-13
   DOI 10.3109/0284186X.2015.1061690, PubMed 26213311
2. Berg J, Fjellbirkeland L, Suhrke P, Jebsen P, Lund-Iversen M, Kleinberg L, Helgeland L, Brustugun OT, Helland Å (2015)
   EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust
   Acta Oncol, 55 (2), 149-55
   DOI 10.3109/0284186X.2015.1062537, PubMed 26313507
3. Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
   Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
   Mol Oncol, 10 (2), 330-43
   DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
4. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
   Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
   Am J Hum Genet, 97 (1), 22-34
   DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
5. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT (2015)
   Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
   Clin Cancer Res, 21 (11), 2635-43
   DOI 10.1158/1078-0432.CCR-14-1905, PubMed 25680376
6. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
   Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
   Genome Biol, 16 (1), 7
   DOI 10.1186/s13059-014-0558-0, PubMed 25650807
7. Helland A (2015)
   Gene jockeys Life science and the rise of biotech enterprise.
   Tidsskr. Nor. Laegeforen., 135 (4), 356
   DOI 10.4045/tidsskr.14.1367
8. Helland A (2015)
   Cancer stem cells
   Tidsskr. Nor. Laegeforen., 135 (8), 783
   DOI 10.4045/tidsskr.15.0031
9. Helland A (2015)
   Viruses and human cancer
   Tidsskr. Nor. Laegeforen., 135 (9), 874
   DOI 10.4045/tidsskr.15.0167
10. Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT (2015)
    NUT expression in primary lung tumours
    Diagn Pathol, 10, 156
    DOI 10.1186/s13000-015-0395-9, PubMed 26341600
11. Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
    Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
    Mol Oncol, 9 (4), 861-76
    DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
12. Syljuåsen RG, Hasvold G, Hauge S, Helland Å (2015)
    Targeting lung cancer through inhibition of checkpoint kinases
    Front Genet, 6, 70
    DOI 10.3389/fgene.2015.00070, PubMed 25774168
13. Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH (2015)
    Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
    PLoS One, 10 (5), e0123542
    DOI 10.1371/journal.pone.0123542, PubMed 25955180

Publications 2014

1. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
   Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
   Cell Rep, 6 (3), 514-27
   DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
2. Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
   Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
   Int J Cancer, 135 (8), 1812-21
   DOI 10.1002/ijc.28828, PubMed 24599520
3. Brustugun OT, Helland Å, Julsrud L (2014)
   [Time counts!]
   Tidsskr Nor Laegeforen, 134 (9), 915
   DOI 10.4045/tidsskr.14.0057, PubMed 24828708
4. Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å (2014)
   BRAF-mutations in non-small cell lung cancer
   Lung Cancer, 84 (1), 36-8
   DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757
5. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M et al. (2014)
   Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
   Nat Commun, 5, 3518
   DOI 10.1038/ncomms4518, PubMed 24670920
6. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   Genome Biol, 15 (8), 435
   DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
7. Halvorsen AR, Helland A, Fleischer T, Haug KM, Grenaker Alnaes GI, Nebdal D, Syljuåsen RG, Touleimat N, Busato F, Tost J, Saetersdal AB, Børresen-Dale AL, Kristensen V, Edvardsen H (2014)
   Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy
   Int J Cancer, 135 (9), 2085-95
   DOI 10.1002/ijc.28862, PubMed 24658971
8. Sagerup CM, Nymoen DA, Halvorsen AR, Lund-Iversen M, Helland A, Brustugun OT (2014)
   Human papilloma virus detection and typing in 334 lung cancer patients
   Acta Oncol, 53 (7), 952-7
   DOI 10.3109/0284186X.2013.879608, PubMed 24446743
9. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
   Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
   J Proteome Res, 13 (5), 2314-27
   DOI 10.1021/pr401092y, PubMed 24669823
10. Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
    GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
    Genome Biol, 15 (8), 442
    DOI 10.1186/s13059-014-0442-y, PubMed 25168174

Publications 2013

1. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
   High levels of genomic aberrations in serous ovarian cancers are associated with better survival
   PLoS One, 8 (1), e54356
   DOI 10.1371/journal.pone.0054356, PubMed 23372714
2. Brustugun OT, Helland Å (2013)
   Rapid reduction in the incidence of cancer of unknown primary. A population-based study
   Acta Oncol, 53 (1), 134-7
   DOI 10.3109/0284186X.2013.783230, PubMed 23550957
3. Kongsgaard A, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
   Osteopontin is a prognostic biomarker in non-small cell lung cancer
   BMC Cancer, 13, 540
   DOI 10.1186/1471-2407-13-540, PubMed 24215488
4. Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R, Brustugun OT, Helland Å (2013)
   Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
   PLoS One, 8 (5), e62153
   DOI 10.1371/journal.pone.0062153, PubMed 23671585
5. Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS (2013)
   Two Distinct Categories of Focal Deletions in Cancer Genomes
   PLoS One, 8 (6), e66264
   DOI 10.1371/journal.pone.0066264, PubMed 23805207

Publications 2012

1. Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L (2012)
   [Mutation testing for non-small-cell lung cancer]
   Tidsskr Nor Laegeforen, 132 (8), 952-5
   DOI 10.4045/tidsskr.11.1017, PubMed 22562326
2. Helland Å, Solberg S, Brustugun OT (2012)
   Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases
   J Thorac Oncol, 7 (12), 1858-1861
   DOI 10.1097/JTO.0b013e318275b346, PubMed 23154557
3. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT (2012)
   Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations
   J Thorac Oncol, 7 (9), 1471-3
   DOI 10.1097/JTO.0b013e3182614a9d, PubMed 22895145
4. Sagerup CM, Småstuen M, Johannesen TB, Helland A, Brustugun OT (2012)
   Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients
   J Thorac Oncol, 7 (1), 57-63
   DOI 10.1097/JTO.0b013e3182307f7e, PubMed 21900838
5. Waldeland E, Brustugun OT, Ramberg C, Helland Å (2012)
   [Stereotactic irradiation in spinal metastases]
   Tidsskr Nor Laegeforen, 132 (22), 2478-9
   DOI 10.4045/tidsskr.12.1108, PubMed 23338027
6. Waldeland E, Ramberg C, Arnesen MR, Helland A, Brustugun OT, Malinen E (2012)
   Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors
   Acta Oncol, 51 (5), 603-9
   DOI 10.3109/0284186X.2012.658115, PubMed 22304490

Publications 2011

1. Berg A, Brustugun OT, Lund-Iversen M, Helland Å (2011)
   Palmar bullous blistering induced by erlotinib
   J Thorac Oncol, 6 (5), 954
   DOI 10.1097/JTO.0b013e318211136b, PubMed 21623268
2. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F et al. (2011)
   Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
   Cancer Discov, 1 (1), 78-89
   DOI 10.1158/2159-8274.CD-11-0005, PubMed 22328973
3. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
   Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
   PLoS One, 6 (4), e18064
   DOI 10.1371/journal.pone.0018064, PubMed 21533284
4. Helland Å, Skaug HM, Kleinberg L, Iversen ML, Rud AK, Fleischer T, Sagerup C, Solberg S, Jørgensen L, Ariansen S, Brustugun OT (2011)
   EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery
   J Thorac Oncol, 6 (5), 947-50
   DOI 10.1097/JTO.0b013e31820db209, PubMed 21623266
5. Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
   Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
   BMC Cancer, 11, 332
   DOI 10.1186/1471-2407-11-332, PubMed 21812955
6. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
   Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
   BMC Med Genomics, 4, 77
   DOI 10.1186/1755-8794-4-77, PubMed 22044755
7. Knudtsen IS, Rødal J, Brustugun OT, Helland Å, Skretting A, Malinen E (2011)
   Dynamic respiratory gated (18)FDG-PET of lung tumors - a feasibility study
   Acta Oncol, 50 (6), 889-96
   DOI 10.3109/0284186X.2011.583266, PubMed 21767189
8. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
   Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
   Proc Natl Acad Sci U S A, 109 (8), 2802-7
   DOI 10.1073/pnas.1108781108, PubMed 21908711
9. Sagerup CM, Småstuen M, Johannesen TB, Helland Å, Brustugun OT (2011)
   Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases
   Thorax, 66 (4), 301-7
   DOI 10.1136/thx.2010.151621, PubMed 21199818
10. Turzer M, Brustugun OT, Waldeland E, Helland A (2011)
    Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity
    Case Rep Oncol, 4 (1), 25-34
    DOI 10.1159/000324113, PubMed 21526003

Publications 2010

1. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
   Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
   Breast Cancer Res, 12 (4), R65
   DOI 10.1186/bcr2632, PubMed 20799965
2. Marienhagen K, Helland A, Nordberg T, Guren MG, Hofsli E (2010)
   [How do Norwegian oncologists perceive their working conditions?]
   Tidsskr Nor Laegeforen, 130 (5), 487-9
   DOI 10.4045/tidsskr.08.0305, PubMed 20224615
3. Turzer M, Brustugun OT, Helland A (2010)
   Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
   Case Rep Oncol, 3 (2), 195-201
   DOI 10.1159/000317104, PubMed 20740196

Publications 2009

1. Helland A, Brustugun OT (2009)
   [Lung cancer in smokers and never-smokers]
   Tidsskr Nor Laegeforen, 129 (18), 1859-62
   DOI 10.4045/tidsskr.08.0652, PubMed 19844277
2. Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
   Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
   Nucleic Acids Res, 37 (12), e89
   DOI 10.1093/nar/gkp413, PubMed 19474344
3. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, Gyllensten U, Haws AL, Helland A, Herrington CS, Hildesheim A, Humbey O, Jee SH, Kim JW, Madeleine MM, Menczer J, Ngan HY, Nishikawa A, Niwa Y et al. (2009)
   TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
   Lancet Oncol, 10 (8), 772-84
   DOI 10.1016/S1470-2045(09)70187-1, PubMed 19625214
4. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
   Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
   PLoS One, 4 (5), e5583
   DOI 10.1371/journal.pone.0005583, PubMed 19440550
5. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
   Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
   Mol Oncol, 4 (2), 98-118
   DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370

Publications 2008

1. Aavitsland P, Helland A (2008)
   [The selected contagions]
   Tidsskr Nor Laegeforen, 128 (20), 2304
   PubMed 19096483

Publications 2007

1. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD (2007)
   Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy
   Int J Radiat Oncol Biol Phys, 67 (4), 1163-71
   DOI 10.1016/j.ijrobp.2006.11.009, PubMed 17336217

Publications 2006

1. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
   Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
   PLoS Med, 3 (3), e47
   DOI 10.1371/journal.pmed.0030047, PubMed 16417408
2. Helland A, Johnsen H, Frøyland C, Landmark HB, Saetersdal AB, Holmen MM, Gjertsen T, Nesland JM, Ottestad W, Jeffrey SS, Ottestad LO, Rodningen OK, Sherlock G, Børresen-Dale AL (2006)
   Radiation-induced effects on gene expression: an in vivo study on breast cancer
   Radiother Oncol, 80 (2), 230-5
   DOI 10.1016/j.radonc.2006.07.007, PubMed 16890317

Publications 2005

1. Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
   PIK3CA mutations in advanced ovarian carcinomas
   Hum Mutat, 25 (3), 322
   DOI 10.1002/humu.9316, PubMed 15712344
2. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
   Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
   Am J Clin Pathol, 124 (3), 392-401
   DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Publications 2004

1. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
   TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
   Br J Cancer, 90 (3), 678-85
   DOI 10.1038/sj.bjc.6601537, PubMed 14760384
2. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
   Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
   Hum Mutat, 24 (1), 21-34
   DOI 10.1002/humu.20055, PubMed 15221786

Publications 2003

1. Kristiansen M, Helland A, Kristensen GB, Olsen AO, Lønning PE, Børresen-Dale AL, Ørstavik KH (2003)
   X chromosome inactivation in cervical cancer patients
   Cancer Genet Cytogenet, 146 (1), 73-6
   DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700